Carl:
I think that Shaman was one of the issues that Jim McCamant mentioned on CNBC yesterday, together with IMGN, XOMA and some others. The other piece of news was a delay, at best and announced yesterday, for SunPharm's competing product.
It's not my favorite company or management team. They recently needed some cash during the current, closed financing period.... they floated a very innovative (read "desperate, strange") preferred financing where the investors could share in revenues from the diarrhea product.
I feel that FDA has said "no" to traveler's diarrhea, and that the target is now exclusively AIDS-related diarrhea.
While I avoid old, tired business plans, I don't know of any imminent downside, so maybe you should go by the chart and what it tells you. Also, I'd say that there is little near-term downside, as it appears that toxicity will not be a problem. I'd therefore bet that there will be a relatively news-free period until the end of phase III testing.
I'd bounce everything that I said off of some thread proponents, to make sure that I haven't said something really off-base. However, I heard the CEO talk at the end of July, so I'm relatively up to date.
Rick |
